Navigation Links
OncoSec to Present at World Cancer Immunotherapy Conference
Date:1/24/2012

SAN DIEGO, Jan. 24, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Michael Cross, Ph.D., Chief Business Officer at OncoSec, will be presenting at the World Cancer Immunotherapy Conference in San Diego, January 25-26, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

World Cancer Immunotherapy Conference
Hilton San Diego Gaslamp Quarter
401 K Street, San Diego, CA
United States 92101
January 25-26, 2012

OncoSec Presentation
January 25, 2012
3:45pm PT

The World Cancer Immunotherapy Conference is bringing together leading scientists from across the globe to present research, case studies and viewpoints on various topics integral to a better understanding of the challenges and opportunities facing developers of therapeutic cancer vaccines.

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agent (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
2. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
3. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
4. OncoSec to Present at Medical Device Investor Forum
5. Device Master File for OncoSec Medical System Completed and Submitted to FDA
6. OncoSec Releases Devices for Use in Clinical Trials
7. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
8. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Medical to Present at Industry and Investor Conferences
11. OncoSec Medical Appoints Engineering Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
(Date:12/2/2016)... to announce that 12 scientific abstracts have been accepted for ... Society (AES) Annual Meeting, which takes place from 2-6 December ... Data being presented include posters further describing ... CV and BRIVIACT ® (brivaracetam) CV. 2,3,4,6,8 Presentations ... union of epilepsy care and antiepileptic drugs in the U.S. ...
(Date:11/30/2016)... DUBLIN , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring ... ... The full report suite on ... cerebrospinal fluid external drainage systems, intracranial pressure monitoring devices, detachable ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek ... Dr. Murthy explains how he was inspired to practice medicine at an early age ... is about more than making diagnoses and prescribing medicine,” he states. “It is about ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
Breaking Medicine News(10 mins):